# A Study To Assess The Safety And Tolerability Of GW642444 In Subjects With Chronic Obstructive Pulmonary Disease (COPD)

> **NCT00372112** · PHASE2 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 68 (actual)

## Conditions studied

- Pulmonary Disease, Chronic Obstructive

## Interventions

- **DRUG:** GW642444
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT00372112
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-11-03
- **Primary completion:** 2007-05-01
- **Final completion:** 2007-05-10
- **Target enrollment:** 68 (ACTUAL)
- **Last updated:** 2018-04-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00372112

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00372112, "A Study To Assess The Safety And Tolerability Of GW642444 In Subjects With Chronic Obstructive Pulmonary Disease (COPD)". Retrieved via AI Analytics 2026-09-16 from https://api.ai-analytics.org/clinical/NCT00372112. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*